降血脂药物专利竞争态势分析

发布时间：2018-11-02 08:46

【摘要】：目的:对国内外降血脂药物专利信息进行情报挖掘,旨在为相关领域的医药研发人员揭示该领域药物的研发现状,分析专利技术的发展阶段,热点技术领域及核心技术,核心专利申请机构等相关信息,也有助于相关制药企业确定研究重心及制定发展战略。方法:采用社会网络分析法、聚类分析法等方法,对国家知识产权局专利检索系统及德温特专利数据库中的降血脂药物专利信息进行分析,分析角度包括:历年专利申请量分析、专利技术生命周期分析、专利申请人数量及合作网络分析、专利技术引文分析及专利技术聚类分析。结果:国内降血脂药物专利申请量以及申请人数量呈上升趋势;专利申请量受地区经济及政策状况的影响明显;科研院校的研发重心集中在化学合成类药物专利,企业重心多集中在天然植物提取物类专利;当前的核心技术集中在他汀类药物及天然植物提取物的研发当中。国际降血脂药物专利申请量呈增长趋势;技术也已进入成熟期,核心机构分别是默克集团、瑞士罗氏制药以及勃林格殷格翰集团,核心企业间的合作较少;热点技术领域集中在传统中药及其制剂、治疗脂质紊乱类药物以及新型胍基衍生物三大领域当中;同时各核心机构在热点技术领域均有较多专利。结论:国内外降血脂药物专利技术的研发热点均集中在传统中药及其制剂、治疗脂质紊乱类药物以及新型胍基衍生物三大领域当中。目前我国的研发水平不断提高,研发队伍不断壮大,其中化学合成类药物的主要研发力量为各大科研院校。同时从总体地域分布来看地区政策对企业的发展有着重要影响。目前国际上的几大核心医药企业合作较少,但科研能力及创新水平较高,其目前关注的重点是PCSK9抑制剂药物的研发,在整体技术都已进入成熟期阶段的情况下,大力开发新技术,能够帮助企业更好的抢占市场先机。
[Abstract]:Objective: to explore the patent information of hypolipidemic drugs at home and abroad in order to reveal the current situation of drug research and development in related fields and analyze the development stage of patent technology, hot technology field and core technology. Relevant information, such as core patent application agencies, can also help pharmaceutical companies determine their research focus and formulate development strategies. Methods: the patent information of hypolipidemic drugs in the patent retrieval system of the State intellectual property Office and the Derwent patent database were analyzed by the methods of social network analysis and cluster analysis. The analysis includes: patent application volume analysis, patent technology life cycle analysis, patent applicant number and cooperation network analysis, patent technology citation analysis and patent technology cluster analysis. Results: the number of patent applications and the number of applicants for hypolipidemic drugs were on the rise in China, and the amount of patent applications was obviously affected by the regional economy and policy. The research and development of scientific research colleges focus on the patent of chemical synthetic medicine, and the focus of enterprises is on the patent of natural plant extract; the current core technology is focused on the research and development of statins and natural plant extracts. The number of international patent applications for hypolipidemic drugs is on the rise, and the technology has entered a mature stage. The core institutions are Merck Group, Swiss Roche Pharmaceutical Group and Brig Ingham Group, with less cooperation among the core enterprises. The hot technology field is concentrated in the traditional Chinese medicine and its preparation, the treatment of lipid disorder drugs and the new guanidinyl derivatives. At the same time, the core institutions have more patents in the hot technology field. Conclusion: the research and development of antilipidemic drugs at home and abroad are focused on traditional Chinese medicine and its preparations, lipids and new guanidinyl derivatives. At present, the R & D level of our country is improving and the R & D team is growing. The main R & D force of chemosynthetic drugs is the major research institutes. At the same time, from the overall geographical distribution, regional policies have an important impact on the development of enterprises. At present, there is little cooperation among the major core pharmaceutical enterprises in the world, but the scientific research capability and innovation level are relatively high. At present, their focus is on the research and development of PCSK9 inhibitor drugs, while the overall technology has entered the mature stage. Vigorously develop new technologies, can help enterprises better seize market opportunities.
【学位授予单位】：山西医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R972.6;F426.72

【参考文献】